Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Novel cancer immunotherapy approach could complement existing CAR-T treatments

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

24 Apr 2025

Manipulating a master regulator prevents tumor growth in mice

A protein identified nearly 40 years ago for its ability to stimulate the production of red blood cells plays a surprising, critical role in dampening the immune system's response to cancer.

24 Apr 2025

Statins linked to better survival in blood cancer patients

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk of dying from their cancer compared to similar patients who were not taking statins, according to a study published today in the journal Blood Advances.

23 Apr 2025

Key enzyme found to influence immune aging and B cell production

Our immune systems weaken as we get older, making fewer cells that fight infection and help us recover from illness and injury. Scientists aren't completely sure why. They may have a better idea now, however, thanks to a new study in GeroScience.

17 Apr 2025

Survey reveals low awareness of innovative cancer treatment among Americans

Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy.

17 Apr 2025

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

CellVoyant leverages AI and live-cell imaging to predict cellular behavior, transforming cell therapy development and making it more accessible and efficient.

16 Apr 2025

Understanding the complex spectrum of Castleman disease

Castleman disease (CD) is a rare, non-clonal lymphoproliferative disorder that manifests with a wide range of histologic and clinical features.

11 Apr 2025

Refining the diagnosis of large granular lymphocytic leukemias and their mimics

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal proliferation of cytotoxic lymphocytes. Among them, T-cell LGLL (T-LGLL) and NK-cell LGLL (NK-LGLL) are the most prominent.

10 Apr 2025

Dynamic BH3 profiling offers personalized lung cancer therapies

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication.

9 Apr 2025

QRICH1 protein discovery opens new avenues for cancer and autoimmune therapies

In a study of the immune systems of mice, scientists at Johns Hopkins Medicine say they have found a new role for a protein, QRICH1, which could become a target for drugs to dial up or down the activation of T cells to fight cancers and autoimmune diseases.

9 Apr 2025

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

Drug-carrying DNA aptamers offer dual action against leukemia stem cells

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana-Champaign report.

3 Apr 2025

HLA-DRB1 molecule can be a potential target in treating acute myeloid leukemia

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells.

1 Apr 2025

New tool helps predict CAR T therapy outcomes for lymphoma patients

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical Center in Los Angeles ranked among the nation's top 5 cancer centers by U.S. News & World Report, and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response to chimeric antigen receptor (CAR) T cell therapy before starting the treatment, according to study results published today in Nature Medicine.

1 Apr 2025

‘They won’t help me’: Sickest patients face insurance denials despite policy fixes

Sheldon Ekirch spends a lot of time on hold with her health insurance company. Sometimes, as the minutes tick by and her frustration mounts, Ekirch, 30, opens a meditation app on her phone. It was recommended by her psychologist to help with the depression associated with a stressful and painful medical disorder.

31 Mar 2025

Fusion proteins enable the creation of monoclonal antibodies

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to advance research projects.

26 Mar 2025

Scientists link emulsifiers in processed foods to allergy and immune disorders

Review identifies common food additives in ultra-processed foods—particularly emulsifiers like carrageenan and polysorbate 80—as key drivers of gut dysbiosis, inflammation, and allergic diseases by disrupting intestinal barriers and activating proinflammatory pathways.

26 Mar 2025